NYSE:IMVIMV Stock Price, Forecast & News

IMV's stock was trading at $2.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IMV stock has increased by 84.5% and is now trading at $4.39. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IMV.

IMV is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for IMV.

Imv Inc (NYSE:IMV) issued its earnings results on Friday, May, 15th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.03. The firm had revenue of $0.05 million for the quarter, compared to analysts' expectations of $0.04 million. View IMV's earnings history.

7 brokerages have issued 12-month price targets for IMV's stock. Their forecasts range from $3.00 to $13.00. On average, they anticipate IMV's share price to reach $7.83 in the next twelve months. This suggests a possible upside of 78.4% from the stock's current price. View analysts' price targets for IMV.

Media headlines about IMV stock have trended positive on Thursday, InfoTrie reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. IMV earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news about IMV.

Some companies that are related to IMV include Trillium Therapeutics (TRIL), PureTech Health (PRTC), Oxford BioMedica (OXB), CEL-SCI (CVM), Aptose Biosciences (APS), Cel-Sci (CVM), SIGA Technologies (SIGA), Paradigm Biopharmaceuticals (PAR), Biotest (BIO), iShares Diversified Alternatives Trust (ALT), Neptune Wellness Solutions (NEPT), Altimmune (ALT), TELIX Pharmaceutical (TLX), Starpharma (SPL) and Ibio (IBIO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other IMV investors own include Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), Gilead Sciences (GILD), Nokia Oyj (NOK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Vaxart (VXRT), ADMA Biologics (ADMA) and Amplify Energy (AMPY).

IMV trades on the New York Stock Exchange (NYSE) under the ticker symbol "IMV."

Shares of IMV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IMV stock can currently be purchased for approximately $4.39.

IMV has a market capitalization of $270.88 million.

The company can be reached via phone at (902) 492-1819.